Woodline Partners’s Acceleron Pharma XLRN Stock Holding History

Woodline Partners’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,173	Closed	-$202K	–	861
2021 Q3	$202K	Buy	+1,173	New	+$153K	﹤0.01%	574
2021 Q2	–	Sell	-52,417	Closed	-$7.11M	–	738
2021 Q1	$7.11M	Buy	+52,417	New	+$6.77M	0.16%	161
2020 Q4	–	Sell	-90,534	Closed	-$10.2M	–	283
2020 Q3	$10.2M	Buy	+90,534	New	+$9.01M	0.33%	84

Woodline Partners's XLRN Position: Q4 2021 in Review

Woodline Partners sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 1,173 shares — an estimated $202K sold.

Woodline Partners first reported a position in XLRN in Q3 2020 and held it in 3 quarters. The position peaked at $10.2M in Q3 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Woodline Partners reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Woodline Partners sold 1,173 Acceleron Pharma shares in Q4 2021, an estimated $202K.
Woodline Partners first reported a position in Acceleron Pharma in Q3 2020 and held it in 3 quarters.
Woodline Partners's Acceleron Pharma position peaked at $10.2M in Q3 2020.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Woodline Partners's 13F filing for Q4 2021, filed 14 Feb 2022.